MapQuant Dx™ Genomic Grade is the cornerstone of the MapQuant Dx™ assay series. It is the very first, microarray-based and clinically-validated, molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.

Resolving histological grading uncertainty

Tumor grade is a decision factor in most national & international guidelines to breast cancer treatment. It is generally recommended to treat high-grade "grade 3" breast carcinoma with chemotherapy because they are chemosensitive and will often recur otherwise. By contrast, most low-grade "grade 1" tumors should not be treated with chemotherapy because they have a good prognosis and often are chemo-insensitive.

A critical clinical issue is how to treat the 50% of breast cancers tested today as intermediate grade?

The MapQuant Dx™ Genomic Grade test now allows to resolve more than 80% of these uncertain "grade 2" tumors into "grade 1" or "grade 3" tumors, potentially sparing useless chemotherapy treatments to tens of thousands patients a year.

By precisely measuring the Genomic Grade index of tumors

MapQuant Dx™ Genomic Grade test is based on the Genomic Grade index (GGi); it directly measures the expression of the 97 genes that best characterize high-grade vs. low-grade tumors. It can resolve these "grade 2" tumors into either "grade 1" or "grade 3" tumors in 80% of cases.

GGi was discovered by oncology researchers at the Institut Jules Bordet (Brussels, Belgium) and ISREC (Lausanne, Switzerland), two leading European cancer research institutes.  Ipsogen holds the exclusive worldwide license of the GGi technologies.